Johnson & Johnson Reports Q1 2020 Results: Oncology Sales Surge Nearly 20%, Full-Year Guidance Lowered Amid Pandemic

On April 14, Johnson & Johnson announced its first-quarter 2020 financial results, reporting revenue of $20.691 billion, a year-over-year increase of 3.3%. The Pharmaceutical segment generated $11.134 billion in revenue (+8.7%), the Medical Devices segment recorded $5.932 billion (-8.2%), and the Consumer Health segment achieved $3.625 billion (+9.2%).

From a product-specific perspective, products in the fields of oncology, autoimmune diseases, and pulmonary arterial hypertension are key drivers sustaining the growth of Johnson & Johnson’s pharmaceutical business. In oncology, Darzalex is poised to succeed Imbruvica as Johnson & Johnson’s flagship cancer drug. Fueled by the rapid growth of these two agents, the oncology segment posted a 19.7% increase, making it the most standout performer within Johnson & Johnson’s portfolio. In the immunology sector, Johnson & Johnson has maintained its market position with its two IL-23 inhibitors.

Johnson & Johnson’s Sales of Major Products in Q1 2020 (USD billion)

Due to the impact of the pandemic, Johnson & Johnson lowered its full-year 2020 financial guidance in its Q1 2020 earnings report. Total revenue expectations were reduced from $85.4–$86.2 billion, as projected in January, to $77.5–$80.5 billion, with the expected growth rate revised downward from 4.0%–5.5% to -5.5%–-2.0%.

Regarding the COVID-19 vaccine, which has drawn significant public attention, Johnson & Johnson announced in early April that its subsidiary, Janssen Pharmaceuticals, would partner with the U.S. Biomedical Advanced Research and Development Authority (BARDA). The two parties will jointly invest over $1 billion in the research and development of a COVID-19 vaccine, with a commitment to supplying one billion doses globally. The implementation roadmap for this initiative was also disclosed in the company’s first-quarter earnings report.

Specifically, Johnson & Johnson secured its vaccine candidate in March, completed pre-manufacturing preparations by June, initiated first-in-human clinical trials in September, obtained preliminary clinical data in December, and was poised to deliver the first batch of vaccines in Q1 2021, sufficient to meet the requirements for Emergency Use Authorization. Throughout this process, Johnson & Johnson simultaneously worked to scale up vaccine production capacity and collaborated closely with external partners.